Exscientia (NASDAQ:EXAI) Sees Large Volume Increase – Here’s Why

by · The Cerbat Gem

Exscientia plc (NASDAQ:EXAI – Get Free Report) shares saw unusually-strong trading volume on Monday . Approximately 1,195,302 shares traded hands during mid-day trading, an increase of 90% from the previous session’s volume of 630,734 shares.The stock last traded at $6.13 and had previously closed at $5.44.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Barclays reiterated an “equal weight” rating and set a $5.00 price target on shares of Exscientia in a research report on Tuesday, August 13th. TD Cowen reaffirmed a “hold” rating on shares of Exscientia in a research report on Friday, August 9th.

Check Out Our Latest Research Report on EXAI

Exscientia Stock Performance

The company has a quick ratio of 5.93, a current ratio of 5.93 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $702.37 million, a price-to-earnings ratio of -4.72 and a beta of 0.83. The company has a 50-day moving average price of $5.00 and a 200-day moving average price of $5.12.

Exscientia (NASDAQ:EXAI – Get Free Report) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.05). The business had revenue of $5.60 million during the quarter. Exscientia had a negative return on equity of 37.56% and a negative net margin of 620.99%. As a group, equities research analysts forecast that Exscientia plc will post -1.25 earnings per share for the current year.

Institutional Trading of Exscientia

A number of hedge funds and other institutional investors have recently modified their holdings of EXAI. China Universal Asset Management Co. Ltd. grew its position in Exscientia by 66.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,576 shares of the company’s stock worth $47,000 after buying an additional 3,821 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Exscientia in the 2nd quarter worth $54,000. International Assets Investment Management LLC acquired a new stake in shares of Exscientia during the third quarter worth $77,000. Federated Hermes Inc. purchased a new stake in shares of Exscientia during the second quarter valued at $115,000. Finally, EntryPoint Capital LLC boosted its position in shares of Exscientia by 22.8% in the 1st quarter. EntryPoint Capital LLC now owns 31,171 shares of the company’s stock valued at $178,000 after purchasing an additional 5,784 shares during the period. Institutional investors own 41.58% of the company’s stock.

Exscientia Company Profile

(Get Free Report)

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.

Featured Stories